30.73USD+0.49%Mkt Cap: 2.41B USDP/E: —Last update: 2026-05-22
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap2.41B USD
Enterprise Value1.95B USD
Revenue (TTM)865.00K USD
Gross Profit-264.60M USD
Net Income (TTM)-258.76M USD
Revenue/Share0.0130 USD
Last Price30.73 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees198
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.72
PEG—
EV/EBITDA-6.38
EV/Revenue2255.19
P/S2774.90
P/B4.46
EPS (TTM)-4.27
EPS (Forward)-4.55
52W Range
18.5571% of range35.79
52W High35.79 USD
52W Low18.55 USD
Profitability
Gross Margin0.00%
Oper. Margin-562900.00%
EBITDA Margin0.00%
Profit Margin-16748.03%
ROE-49.08%
ROA-44.38%
Growth
Revenue Growth-97.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-210.94M USD
CapEx (TTM)2.71M USD
FCF Margin-14597.85%
FCF Yield-5.23%
Net Debt-449.55M USD
Net Debt/EBITDA1.47
Balance Sheet
Debt/Equity0.00
Current Ratio8.92
Quick Ratio8.78
Book Value/Sh6.853 USD
Cash/Share5.752 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateFeb 11, 2019
Splits
Last Split1:15
Split DateFeb 11, 2019
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)58.43 USD
Target Range38.00 USD – 90.00 USD
# Analysts14
Ownership
Shares Out.78.49M
Float72.46M
Insiders0.27%
Institutions94.45%
Short Interest
Short Ratio6.7d
Short % Float11.49%
Short % Out.9.68%
Shares Short7.60M
Short (prev mo.)9.08M
Technical
SMA 5032.06 (-4.1%)
SMA 20027.24 (+12.8%)
Beta0.98
S&P 52W Chg28.31%
Avg Vol (30d)772.38K
Avg Vol (10d)797.99K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—